People with diabetes often hear about medicines that may reduce heart risk. Low-dose colchicine is one of those medicines, but it needs careful framing because it is not a general diabetes treatment.
Quick summary
The U.S. label for LODOCO, a 0.5 mg colchicine tablet, describes use to reduce risks such as heart attack, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple cardiovascular risk factors.
Key takeaways
- Colchicine is an anti-inflammatory medicine, not a glucose-lowering drug.
- Trials such as LoDoCo2 studied low-dose colchicine in people with chronic coronary disease.
- Diabetes can raise cardiovascular risk, but that does not mean every person with diabetes should take colchicine.
- Kidney disease, liver disease, blood disorders, and drug interactions can make colchicine unsafe.
Why this is relevant to diabetes
Diabetes is one of several conditions that can increase cardiovascular risk. Current diabetes heart-care guidance still centers on proven basics such as blood pressure control, cholesterol management, smoking cessation, kidney protection, healthy activity, and selected glucose-lowering medicines with heart or kidney benefit when appropriate.
Colchicine should not be framed as routine primary prevention for everyone with diabetes. The labeled cardiovascular use is for selected adults with established atherosclerotic disease or multiple cardiovascular risk factors, and the decision belongs in a clinician visit because the safety screen is important.
Important cautions
- Do not use gout colchicine instructions as a heart-risk plan.
- Do not combine colchicine with certain strong CYP3A4 or P-glycoprotein inhibitors unless a clinician confirms safety.
- Tell your clinician about kidney disease, liver disease, blood disorders, statins, antibiotics, antifungals, and all supplements.
- Report severe diarrhea, muscle weakness, numbness, unusual bruising, or signs of infection promptly.
Practical takeaway
For people with diabetes, colchicine is a cardiology conversation, not a self-start supplement or a replacement for standard heart-risk care.
Safety note
This article is not a substitute for medical care. Do not start, stop, or change colchicine without your clinician, especially if you have kidney or liver problems or take medicines that interact.
What to ask your care team
- Do I have established atherosclerotic disease or multiple cardiovascular risk factors?
- Could colchicine interact with any of my medicines?
- Which heart-risk steps are highest priority for me right now?
Source summary
- LODOCO colchicine tablets 0.5 mg prescribing information, DailyMed, National Library of Medicine. FDA label repository. Accessed June 5, 2026. Source
- Colchicine in Patients with Chronic Coronary Disease, New England Journal of Medicine. Randomized trial report. Accessed June 5, 2026. Source
- Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease 2, American College of Cardiology. Trial summary. Accessed June 5, 2026. Source
- Cardiovascular Disease and Risk Management: Standards of Care in Diabetes 2026, American Diabetes Association, Diabetes Care. Clinical guideline. Accessed June 5, 2026. Source